89 results about "CDK inhibitor" patented technology

Described herein are compositions comprising a lanthanide (III) modified fatty acid and methods of treating cancer with the composition. In particular, the application includes a lanthanide (III) modified fatty acid is a 9-R′, 10-R″ tri octadecanoate compound. This lanthanide (III) modified fatty acid can be combined with additional therapeutic agents, such as chemotherapeutic agents, radiopharmaceuticals, hormone therapies, CDK inhibitors, epigenetic modulators, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors, phosphatidyl inositol-3-posphate kinase inhibitors, ATP-adenosine axis-targeting agents, signal transduction inhibitors, RAS signaling inhibitors, PI3K inhibitors, arginase inhibitors, HIF inhibitors, AXL inhibitors, PAK4 inhibitors, immunotherapeutic agents, immune checkpoint inhibitors, and agonists of stimulatory or co-stimulatory immune checkpoints.

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.

The present application provides CDK inhibitors. Specifically, the invention provides a compound which can be used for treating cancers and is represented by a structural formula (I) or pharmaceutically acceptable salts or stereoisomers thereof. # imgabs0 #

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K / Akt / mTOR pathway or a pharmaceutically acceptable salt thereof.

The invention provides a compound represented by represented by the following strutural formula:or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

To provide methods and compositions for controlling sucker growth in tobacco by altering the expression of different target genes.SOLUTION: A modified tobacco plant comprises a mutation in an endogenous gene encoding polypeptide selected from the group consisting of cyclin, cyclin-dependent kinase (CDK), a CDK inhibitor, MYB, and a WRKY transcription factor, wherein the mutation is not present in the endogenous gene in a control tobacco plant of the same variety, and wherein the modified tobacco plant comprises no suckers or reduced suckers after topping as compared to the control tobacco plant when grown under comparable growth conditions.SELECTED DRAWING: None

Various salt forms and free bases of compound (I) represented by the following chemical formula are disclosed (I).

The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg. AZD9833 may be administered alone or its use may be in combination with an additional anti-cancer agent such as a CDK inhibitor, everolimus or an AKT inhibitor.

Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

The present disclosure discloses a class of novel compounds that are selective CDK8 / CDK19 inhibitors, pharmaceutical compositions containing the compounds, useful intermediates for preparing the compounds, and methods of treating cell proliferative diseases, such as cancer, using the compounds of the disclosure. The compound has a structure as shown in a formula (I). # imgabs0 #

Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K / Akt / mTOR pathway or a pharmaceutically acceptable salt thereof.

The present invention relates to a CDK inhibitor and the pharmaceutical uses thereof. In particular, the present invention relates to a CDK inhibitor having a structure of formula (I), a pharmaceutical composition thereof, the use thereof as a CDK inhibitor, and the use thereof in the preparation of a drug for treating at least part of CDK-related cancers or tumors, each substituent in formula (I) being as defined in the description.

Provided herein are CDK inhibitor compounds having a fused 6-6 bicyclic heteroaryl core, such as naphthyridine, quinazoline, pyridopyrimidine or a further substituted associated electron isosteric core structure. The core structure may be substituted with an amino group, wherein the amino group is further substituted with a cyclic group having an additional hydrophilic group. Also provided herein are compositions comprising the subject CDK inhibitor compounds. In some embodiments, the CDK inhibitor compound is a CDK2 inhibitor or a CDK4 inhibitor. Methods of using the compositions of the present disclosure in research or as therapeutic agents are also provided.

The application provides a polymorph of a compound of formula (A) (N-(1-((4-((3S,5S)-3,5-dimethylpiperazin-1-yl)phenyl)sulfonyl)piperidin-4-yl)-4-((S)-tetrahydrofuran-3-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-amine) and a polymorph of a phosphate salt of the compound of formula (A). The crystal form provided by the application has good chemical stability, physical stability and low hygroscopicity, is less affected by temperature, humidity and light, and is convenient to store and develop into a preparation.

Various salt forms and free base of Compound (I) represented by the following formula are disclosed.

Various salt forms and free base of Compound (I) represented by the following formula are disclosed.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof and methods of inhibiting the activity of CDK enzyme using the compounds and compositions of the present disclosure. The present disclosure further relates to, but is not limited to, methods of treating disorders associated with CDK signaling using the compounds and compositions of the present disclosure.

Provided herein are CDK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provide herein is a method of their use for treating, preventing, or ameliorating a chemotherapy-induced gastrointestinal side effect.

The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.

Provided herein are methods of treating diseases, disorders, or conditions including cancers, where the methods comprise administration of Compound 1, or a pharmaceutically acceptable salt thereof, in combination with a CDK inhibitor or a selective estrogen receptor degrader (SERB), as described herein. Such methods may comprise the treatment of cancer, such as breast cancer.

Disclosed herein are bicyclic compound derivatives useful as cyclin dependent kinase inhibitors. Disclosed herein are the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of these compounds for the treatment of cancer.

The present application relates to dosage regimens for the treatment of cancer. The present specification relates to AZD9833 for use in the treatment of cancer and a method of cancer treatment comprising administration of AZD9833 wherein, in each case, the AZD9833 is orally administered once a day at a dose of 25 mg to 450 mg. AZD9833 can be administered alone and can also be used in combination with additional anti-cancer agents such as a CDK inhibitor, everolimus or an AKT inhibitor.

The invention relates to a CDK inhibitor with a structure as shown in a formula (I) and a pharmaceutical composition thereof, and application of the CDK inhibitor as the CDK inhibitor and application of the CDK inhibitor in preparation of drugs for treating at least part of cancers or tumors related to CDK. Wherein each substituent in the formula (I) is as defined in the specification.

Provided are a novel compound, a use thereof for inhibiting the activity of CDK12 and / or CDK13 and degrading cyclin K, a pharmaceutical composition comprising same, and a use for the treatment of diseases associated with CDK12 and / or CDK13 and / or cyclin K, such as cancer. According to the present invention, the compounds exhibit excellent inhibitory activity and selectivity against CDK12 and / or CDK13, and induce degradation of cyclin K, and thus can be useful for the treatment of cancers such as breast cancer or gastric cancer.